Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, PhD, Yasuhito Nannya, MD PhD, Tetsuichi Yoshizato, MD PhD, Robert P. Hasserjian, MD, Ryunosuke Saiki, Yusuke Shiozawa, MD PhD, Sean M. Devlin, PhD, Heinz Tuechler, Araxe Sarian, Luca Malcovati, MD, Francesc Sole, PhD, Detlef Haase, MD, Maria Creignou, Max Levine, MS, Ulrich Germing, MD, Catherine Cargo, MB, FRCPath, Yanming Zhang, MD, Juan Medina, MS, Juan E. Arango Ossa, BS, Julie Schanz, MD PhD, Arjan van de Loosdrecht, MD PhD, Martin Jädersten, MD PhD, John M. Bennett, MD, Magnus Tobiasson, MD PhD, Olivier Kosmider, PharmD, PhD, Matilde Y Follo, PhD, Felicitas Thol, MD, Ronald F Pinheiro, MD, Valeria Santini, MD, Ioannis Kotsianidis, Jacqueline Boultwood, Fabio PS Santos, MD, Senji Kasahara, MD PhD, Takayuki Ishikawa, MD PhD, Hisashi Tsurumi, MD PhD, Akifumi Takaori-Kondo, MD PhD, Toru Kiguchi, Chantana Polprasert, MD, Virginia M. Klimek, MD, Michael R. Savona, MD, Monika Belickova, PhD, Christina Ganster, Lionel Ades, MD PhD, Matteo Giovanni Della Porta, MD, Alexandra Smith, PhD, Yesenia Werner, Minal A Patel, MPH, Agnes Viale, PhD, Katelynd Vanness, Donna S Neuberg, ScD, Kristen E. Stevenson, MS, Kamal Menghrajani, MD, Kelly Bolton, MD PhD, Pierre Fenaux, MD PhD, Andrea Pellagatti, Uwe Platzbecker, MD, Michael Heuser, MD, Peter Valent, MD, Shigeru Chiba, MD PhD, Yasushi Miyazaki, MD PhD, Carlo Finelli, Maria Teresa Voso, MD, Lee-Yung Shih, MD, Michaela Fontenay, MD PhD, Joop H. Jansen, PhD, José Cervera, MD PhD, Yoshiko Atsuta, MD PhD, Norbert Gattermann, MD, Benjamin L. Ebert, MD PhD, Rafael Bejar, MD PhD, Peter L Greenberg, MD, Mario Cazzola, MD, Eva Hellstrom Lindberg, MD PhD, Seishi Ogawa, MD PhD, Elli Papaemmanuil, PhD

Blood (2019) 134 (Supplement_1): 675.

https://doi.org/10.1182/blood-2019-129392

Published: 2019

Journal Articles

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

Blood (2019) 134 (Supplement_1): 2994.

https://doi.org/10.1182/blood-2019-126778

Published: 2019

Journal Articles

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Blood (2019) 134 (Supplement_1): 3007.

https://doi.org/10.1182/blood-2019-126671

Published: 2019

Journal Articles

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Blood (2018) 132 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2018-99-114216

Published: 2018

Journal Articles

Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes

Christina Ganster, Katayoon Shirneshan, Sascha Dierks, Roman Martin, Bertram Glass, Haifa Kathrin Al-Ali, Michael Metz, Ulrich Germing, MD, Uwe Platzbecker, MD, Nicolaus Kroeger, Friederike Braulke, Julie Schanz, Lorenz Truemper, Detlef Haase

Blood (2017) 130 (Supplement 1): 4260.

https://doi.org/10.1182/blood.V130.Suppl_1.4260.4260

Published: 2017

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Roxana Schaab, Christina Ganster, PhD, Sascha Dierks, PhD, Katayoon Shirneshan, PhD, Marc Talló Parra, Roman Martin, PhD, Ulrich Germing, Uwe Platzbecker, MD, Frank Lange, MD, Nicolaus Kroeger, MD, Konstanze Döhner, MD, Bertram Glass, MD, Maike Nickelsen, MD, Reingard Stuhlmann, MD, Lorenz H. Truemper, MD, Julie Schanz, MD, Ulrike Bacher, MD, Detlef Haase, MD

Blood (2016) 128 (22): 2001.

https://doi.org/10.1182/blood.V128.22.2001.2001

Published: 2016

Journal Articles

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Blood (2016) 128 (16): 2096–2097.

https://doi.org/10.1182/blood-2016-07-728766

Published: 2016

Journal Articles

Time-dependent changes in mortality and transformation risk in MDS

Blood (2016) 128 (7): 902–910.

https://doi.org/10.1182/blood-2016-02-700054

Published: 2016

Includes: Supplemental data

Journal Articles

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Blood (2015) 126 (23): 2879.

https://doi.org/10.1182/blood.V126.23.2879.2879

Published: 2015

Journal Articles

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Julie Schanz, MD PhD, Friederike Braulke, MD, Ghulam J. Mufti, MD PhD, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, MD, Ulrich Germing, Stefan Schmitz, MD PhD, Peter Haas, MD, Michael Lübbert, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, Florian Nolte, Wolf-Karsten Hofmann, MD PhD, Detlef Haase

Blood (2014) 124 (21): 4656.

https://doi.org/10.1182/blood.V124.21.4656.4656

Published: 2014

Journal Articles

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

Elena Crisà, MD, Esperanza Such, PhD, Steven Best, PhD, Austin Kulasekararaj, José Cervera, Vera Adema, PhDstudent, Nicholas Lea, PhD, Dario Ferrero, MD PhD, Bernardino Allione, Julie Schanz, MD PhD, Detlef Haase, MD, Guillermo F. Sanz, MD PhD, Francesco Sole, PhD, Ghulam J. Mufti, MD PhD

Blood (2014) 124 (21): 4662.

https://doi.org/10.1182/blood.V124.21.4662.4662

Published: 2014

Journal Articles

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

Blood (2013) 122 (21): 1544.

https://doi.org/10.1182/blood.V122.21.1544.1544

Published: 2013

Journal Articles

Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response – , Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE)

Katayoon Shirneshan, PhD, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Aristoteles Giagounidis, MD, Katharina Götze, M.D., Richard F. Schlenk, MD, Michael Lübbert, MD, Gesine Bug, MD, PhD, Friederike Braulke, Julie Schanz, MD, Ulrich Germing, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2783.

https://doi.org/10.1182/blood.V122.21.2783.2783

Published: 2013

Journal Articles

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Julie Schanz, MD, Friederike Braulke, Katayoon Shirneshan, PhD, Kathrin Nachtkamp, MD, Ulrich Germing, MD, Stephan Schmitz, MD, Peter Haas, MD, Michael Lübbert, MD, Catharina Müller-Thomas, MD, Katharina Götze, Uwe Platzbecker, MD, PhD, Florian Nolte, MD, Wolf-Karsten Hofmann, MD, Detlef Haase, MD

Blood (2013) 122 (21): 2784.

https://doi.org/10.1182/blood.V122.21.2784.2784

Published: 2013

Journal Articles

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Catharina Müller-Thomas, MD, Martina Rudelius, MD, Ina Rondak, PhD, Torsten Haferlach, MD, Julie Schanz, MD, Burkhard Schmidt, MD, Markus Kremer, MD, Ulrich Germing, MD, Uwe Platzbecker, MD, PhD, Christian Peschel, Katharina Götze, MD

Blood (2013) 122 (21): 2797.

https://doi.org/10.1182/blood.V122.21.2797.2797

Published: 2013

Journal Articles

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

Christina Ganster, Katayoon Shirneshan, Gabriela Salinas-Riester, Friederike Braulke, Julie Schanz, Katharina S. Götze, Gesine Bug, Peter Majunke, Aristoteles Giagounidis, Catharina Müller-Thomas, Andrea Kündgen, Ulrich Germing, Lorenz Trümper, Uwe Platzbecker, MD, Detlef Haase

Blood (2012) 120 (21): 4926.

https://doi.org/10.1182/blood.V120.21.4926.4926

Published: 2012

Journal Articles

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Blood (2012) 120 (21): 3816.

https://doi.org/10.1182/blood.V120.21.3816.3816

Published: 2012

Journal Articles

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Blood (2012) 120 (12): 2454–2465.

https://doi.org/10.1182/blood-2012-03-420489

Published: 2012

Includes: Supplemental data

Journal Articles

Proof of Y-Loss As Clonal Abnormality in MDS by Comparative Analysis of CD34+ and CD3+ Peripheral Blood Cells,

Christina Ganster, Friederike Braulke, Katayoon Shirneshan, Dietrich Kämpfe, Uwe Platzbecker, MD, Ulrike Söling, Carsten P Bramlage, Tobias J Legler, Detlef Haase, Julie Schanz

Blood (2011) 118 (21): 3800.

https://doi.org/10.1182/blood.V118.21.3800.3800

Published: 2011

NARROW

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Mutation Profile of PPM1D and TP53 in Patients with Myelodysplastic Syndromes and Complex Chromosome Abnormalities

TP53 Status As Well As Cytogenetic Complexity Significantly Impact on Prognosis in Myelodysplastic Syndromes with Complex (≥3 anomalies) Aberrant Karyotypes

Molecular Profile and Cytomorphological Manifestation of Isolated Y Loss in Myelodysplastic Syndromes

Acquisition Patterns and Interaction of Molecular, Obvious and Cryptic Cytogenetic Abnormalities in Myelodysplastic Syndromes

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Time-dependent changes in mortality and transformation risk in MDS

Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes

Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R

Multi-Center Study on Myelodysplastic Syndromes with Isolated Partial or Total Loss of Chromosome 7

Time Changes In Predictive Power Of MDS Prognostic Scores – Effects On Revised Scores Such As The IPSS-R, Impact Of Age

Therapy With Demethylating Agents Significantly Improves Overall- and AML-Free Survival In Patients With MDS Classified As High-Risk By IPSS Or Very High Risk By IPSS-R and Partial Or Total Monosomy 7-Results From a German Multicenter Study

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

A Comprehensive Genetic Analysis of MDS Patients From Peripheral Blood Combining FISH- and SNP-Array-Analysis

CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Proof of Y-Loss As Clonal Abnormality in MDS by Comparative Analysis of CD34+ and CD3+ Peripheral Blood Cells,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only